Seeking Alpha

In the healthcare space, it is somewhat rare to find a true growth company. Most of the growth companies that people talk about in the industry are really medical device companies or drug companies. AmSurg (AMSG) is definitely an exception to this rule though. The company is involved in acquiring and developing ambulatory surgery centers in partnership with physicians groups around the country. Trading at roughly 19X trailing EPS (and ~16.5X CY 2014 expected EPS), AMSG definitely is not cheap. That said, this premium valuation is more than fully justified by the company's ~14% sales growth rate and 10% net income growth rate over the last decade. AMSG has been remarkably consistent on that front in fact, with...

Only subscribers can access this article, which is part of the PRO research library covering 3,776 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: